Buffalo Sabres home arena to remain KeyBank Center after reaching 10-year naming rights extension
Article content
The new deal will kick in next year and run through 2035-36.
Article content
Article content
The Cleveland-based bank has a large regional presence in Buffalo, and took over the downtown arena's naming rights after acquiring First Niagara Bank in 2016. As part of the extension, the bank's name will be featured on the Sabres' helmets for away games starting this season.
Article content
Article content
The arena is undergoing a series of long-needed renovations since first opening in 1996. Last year, the Sabres replaced the roof and installed a new video scoreboard over center ice. The next series of renovations are expected to address upgrading the seats and fan amenities.
Article content
The Sabres' control the building, which is also home to the three-time defending National Lacrosse League champion Bandits, and have placed an emphasis on adding more events since Pete Guelli took over as the team's chief operating officer last year.
Article content
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
44 minutes ago
- Globe and Mail
TELUS International Reports Q2 2025 Financial Results with Increased Revenue but Net Loss
Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. TELUS International (CDA) ( (TSE:TIXT)) has issued an update. On August 1, 2025, TELUS International (CDA) Inc. released its unaudited financial results for the three and six months ended June 30, 2025. The company reported a revenue increase compared to the previous year, but faced a net loss due to higher operating expenses, including significant amortization and impairment costs. This financial performance may impact the company's market positioning and stakeholder confidence. The most recent analyst rating on (TSE:TIXT) stock is a Buy with a C$6.50 price target. To see the full list of analyst forecasts on TELUS International (CDA) stock, see the TSE:TIXT Stock Forecast page. Spark's Take on TSE:TIXT Stock According to Spark, TipRanks' AI Analyst, TSE:TIXT is a Neutral. TELUS International's stock is bolstered by strong cash flow and solid technical indicators, suggesting potential for future gains. However, challenges in profitability, valuation concerns due to a negative P/E ratio, and financial pressures highlighted in the earnings call temper the overall score. To see Spark's full report on TSE:TIXT stock, click here. TELUS International (CDA) Inc. operates in the technology services industry, offering digital customer experience solutions and IT services. The company focuses on providing innovative solutions to enhance customer interactions and streamline business processes. Average Trading Volume: 260,422 Technical Sentiment Signal: Sell Current Market Cap: C$1.44B Find detailed analytics on TIXT stock on TipRanks' Stock Analysis page.
Globe and Mail
an hour ago
- Globe and Mail
TELUS Reports Q2 2025 Growth and Strategic Infrastructure Sale
Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Telus ( (TSE:T)) has shared an announcement. On August 1, 2025, TELUS Corporation announced its second-quarter 2025 financial results, highlighting a 2% increase in consolidated operating revenues to $5.1 billion, driven by strong customer growth in its mobile and fixed services. The company reported an 11% rise in free cash flow and reaffirmed its financial targets for 2025. TELUS also announced a significant transaction with La Caisse, selling a 49.9% stake in its wireless tower infrastructure operator Terrion for $1.26 billion, which is expected to aid in reducing its leverage ratio. Despite recognizing a $500 million impairment related to TELUS Digital, the company remains focused on sustainable growth and enhancing shareholder value. The most recent analyst rating on (TSE:T) stock is a Buy with a C$24.00 price target. To see the full list of analyst forecasts on Telus stock, see the TSE:T Stock Forecast page. Spark's Take on TSE:T Stock According to Spark, TipRanks' AI Analyst, TSE:T is a Neutral. Telus exhibits strong financial performance with effective cost management and cash flow generation. The technical analysis suggests stable market conditions, while the high dividend yield adds attractiveness despite a higher P/E ratio. Positive corporate events further enhance Telus's financial strategy and market standing. To see Spark's full report on TSE:T stock, click here. More about Telus TELUS Corporation is a leading Canadian telecommunications company that provides a wide range of telecommunications products and services including mobile and fixed-line services, internet, and television. The company is also heavily invested in health technology through its TELUS Health segment, and it focuses on expanding its PureFibre connectivity across Canada. Average Trading Volume: 3,512,550 Technical Sentiment Signal: Strong Buy Current Market Cap: C$34.04B Learn more about T stock on TipRanks' Stock Analysis page.
Globe and Mail
an hour ago
- Globe and Mail
If You'd Invested $1,000 in AbbVie (ABBV) Stock 10 Years Ago, Here's How Much You'd Have Today
Key Points If you'd invested in AbbVie 10 years ago, you would likely be pleased. The drugmaker has paid and grown its dividend quite well over this period. Its two immunosuppressants, Skyrizi and Rinvoq, have seen expanding sales. 10 stocks we like better than AbbVie › Think back to 10 years ago. The New England Patriots and their quarterback Tom Brady were accused of underinflating footballs. The Supreme Court affirmed same-sex marriage nationwide. And Apple introduced its Apple Watch. Also, as happens in every year, many investors bought stocks. What if you'd spent $1,000 on shares of AbbVie (NYSE: ABBV) stock a decade ago? What would that stake be worth now? It would be worth $3,350 -- or, if you'd reinvested your dividends in additional shares of AbbVie stock, it would be worth $4,105. That's because AbbVie is a solid dividend payer, with a recent dividend yield of 3.4%. It's a dividend grower, too. Its total annual payout was recently $6.47 per share, up from $5.64 in 2022 and $3.59 in 2018. Before you kick yourself about missing out on this investment, know that it was actually close to average, with dividends not reinvested. AbbVie's average annual gain was 12.84%, compared to 12.62% for the S&P 500 index. When you reinvest dividends for both, AbbVie is more clearly ahead, 15.17% vs. 13.59%. AbbVie was spun off from Abbott Laboratories in 2013, and it's a major global pharmaceutical company with a recent market value topping $330 billion. The company is known for treatments in the fields of immunology, oncology, aesthetics, neuroscience, and eye care. A downside for investors is that it lost patent protection for its blockbuster drug Humira -- but it has a promising pipeline of drugs in development, and two immunosuppressants, Skyrizi and Rinvoq, have been selling well. It's not too late to invest in AbbVie if you like what you see with the company. At recent levels, the stock seems neither wildly overvalued nor undervalued. Its recent price-to-sales ratio of 5.9 is a bit above its five-year average of 4.7, but that's not necessarily a deal-breaker for long-term investors. Perhaps in 2035, you'll be looking back and smiling. Should you invest $1,000 in AbbVie right now? Before you buy stock in AbbVie, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and AbbVie wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $624,823!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,064,820!* Now, it's worth noting Stock Advisor's total average return is 1,019% — a market-crushing outperformance compared to 178% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 29, 2025
